Abstract
Introduction A phenomenon known as the obesity paradox has been reported in patients with heart failure (HF) suggesting lower mortality with increasing weight. The goal of this study is to characterize this observation in HF using the largest available inpatient database of adult patients.
Method We searched the National Inpatient Sample (NIS) database for patients for the years 2016-2020 with a diagnosis of systolic (SHF) or diastolic heart failure (DHF) using International Classification of Diseases, Tenth Revision (ICD-10) diagnosis codes. We evaluated mortality association based on body weight. Multivariate statistical analysis was performed to adjust all-cause inpatient mortality for comorbidities.
Results There was a total of 7,364,023 patients with a diagnosis of SHF and 10,064,223 patients with a diagnosis of DHF. All-cause inpatient mortality was lowest in overweight patients followed by those with obesity and morbid obesity, whereas mortality was highest in cachexia compared to normal weight for SHF and DHF patients (mortality: overweight 2.56%, obese 3.12%, morbidly obese 3.70%, normal weight 5.60%, and cachexia 15.22%; p<0.001) and DHF patients (mortality: overweight 2.08%, obese 2.43%, morbidly obese 2.93%, normal weight 4.58%, and cachexia 14.25%; p<0.001). This relationship remains similar after multivariate analysis. (SHF patients: overweight OR: 0.49 (0.41-0.58), obesity OR: 0.64 (0.62-0.66), morbid obesity OR: 0.85 (0.83-0.88), and cachexia OR: 2.78 (2.67-2.90); p<0.001; DHF patients: overweight OR: 0.47 (0.40-0.56), obesity OR: 0.61 (0.59-0.63), morbid obesity OR: 0.83 (0.81-0.85), and cachexia OR: 3.09 (2.96-3.23); p<0.001).
Conclusion Our data observed that all-cause inpatient mortality in SHF and DHF is lowest in overweight populations followed by obese and morbidly obese populations whereas cachexia has the highest mortality. However, increasing weight above the overweight reduces the obesity paradox benefit.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
It was Exept by University of Arizona IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors had full access to study data and an active role in writing manuscript. Mohammad Reza Movahed: Protocol design and the study, writing, finding ICD codes Austin Mineer: Writing the manuscript, conception of method, finding ICD codes Mehrtash Hashemzadeh: Performing statistical analysis and writing the manuscript
Data Availability
NIS data base publically available
